Abstract: Methods and systems for performing mass spectrometry are provided herein. The method includes ionizing one or more compounds to generate ions, passing the ions into an ion mobility spectrometer, providing ozone, reacting the ions with ozone to produce ozone-induced fragment ions, and performing mass analysis and detection of the ozone-induced fragment ions. The system can comprise an ion source for ionizing one or more compounds to generate ions, an ion mobility spectrometer for receiving and separating the ions, an ozone supply for introducing ozone into the system; a reaction region for reacting the ions with the ozone to produce ozone-induced fragment ions, and a mass spectrometer for performing mass analysis and detection of the ozone-induced fragment ions.

Abstract: Methods and systems for performing ion mobility spectrometry are provided herein. In accordance with various aspects of the applicant's teachings, the methods and systems can provide for the separation of biologically relevant acids that may be difficult to separate with conventional MS techniques. In various aspects, methods and systems in accordance with applicant's teachings can enable a differential mobility spectrometer to resolve biologically relevant acids through the use of CO2 as the drift gas in combination with Acetone.

Abstract: Methods and systems for performing mass spectrometry of analytes labeled with isobaric tags are provided herein. In accordance with various aspects of the applicants' teachings, the methods and systems can enable enhanced discrimination between an analyte of interest and one or more interfering species when using isobaric tagging techniques.

Abstract: Methods and systems for performing ion mobility spectrometry are provided herein. In accordance with various aspects of the applicant's teachings, the methods and systems can provide for the separation of biologically relevant acids that may be difficult to separate with conventional MS techniques. In various aspects, methods and systems in accordance with applicant's teachings can enable a differential mobility spectrometer to resolve biologically relevant acids through the use of CO2 as the drift gas in combination with Acetone.

Abstract: The present invention provides isoxazoline FAAH inhibitors of the formula (I): or pharmaceutically acceptable forms thereof, wherein each of G, Ra, Rb, Rc, and Rd are as defined herein. The present invention also provides pharmaceutical compositions comprising a compound of formula (I), or a pharmaceutically acceptable form thereof, and a pharmaceutically acceptable excipient. The present invention also provides methods for treating an FAAH-mediated condition comprising administering a therapeutically effective amount of a compound of formula (I), or pharmaceutically acceptable form thereof, to a subject in need thereof.

Abstract: An electrospray ion source method and system is provided for detecting emitter failure comprising a liquid chromatography column suitable for chromatographic separation of a sample. The column can have an inlet for receiving the sample; and an outlet for ejecting the sample. A make-up flow channel is provided for introducing make-up flow of liquid to the sample post-column, wherein the make-up flow normalizes the spray current. An electrospray ionization source is provided having one or more electrospray ionization emitter nozzles for receiving the make-up flow containing sample. A power supply can provide a voltage to the one or more emitter nozzles, and a measurement device can measure and monitor the spray current.

Abstract: The present invention relates to compounds formula (I): and to salts thereof, wherein R1-R4 and A have any of the values defined in the specification, and compositions and uses thereof. The compounds are useful as inhibitors of histone demethylases, such as KDM5. Also included are pharmaceutically acceptable compositions comprising the compounds of the present invention and methods of using said compositions in the treatment of various disorders.

Abstract: Fused aromatic phosphonates of structural formula I are precursors to inhibitors of protein tyrosine phosphatase-1B (PTP-1B). The compounds of the present invention are therefore useful for the treatment in a mammal of a disorder, condition, or disease responsive to inhibition of protein tyrosine phosphatase-1B, including Type 2 diabetes, insulin resistance, a lipid disorder, obesity, Metabolic Syndrome, and cancer.

Abstract: An apparatus, system and method of providing that allow for the generation of reagent ions within an inner region of a mass spectrometer for use in ion-ion reactions such as PTRs and ETD using a reagent ion generator. The location where these reagent ions are generated can be as close as possible to the point of action, or the reaction zone where the reagent ion and analyte ions will interact via ion-ion reactions to cause, e.g., PTRs and/or ETD.

Abstract: An apparatus and method for a sample using a mass spectrometer is described, including, generating ions of a first polarity from an analyte using electrospray ionization; generating ions of a second polarity from a reagent; injecting the ions of the first polarity and ions of the second polarity in sequence into a chamber of the mass spectrometer such that the ions of the first polarity and the ions of the second polarity interact in the chamber to form analyte ions having the second polarity; and, analyzing the mass spectrum of the analyte ions of the second polarity. A reagent such as a polyamidomine is selected to preferentially yield analyte ions of the second polarity having a desired mass-to-charge ratio.

Abstract: The present invention provides isoxazoline FAAH inhibitors of the formula (I): or pharmaceutically acceptable forms thereof, wherein each of G, Ra, Rb, Rc, and Rd are as defined herein. The present invention also provides pharmaceutical compositions comprising a compound of formula (I), or a pharmaceutically acceptable form thereof, and a pharmaceutically acceptable excipient. The present invention also provides methods for treating an FAAH-mediated condition comprising administering a therapeutically effective amount of a compound of formula (I), or pharmaceutically acceptable form thereof, to a subject in need thereof.

Abstract: The present invention relates to compounds useful as inhibitors of bromodomain-containing proteins. The invention also provides pharmaceutically acceptable compositions comprising compounds of the present invention and methods of using said compositions in the treatment of various disorders.

Abstract: An apparatus and method are provided for analyzing samples of molecules. The apparatus comprises a mass analysis system including a differential mobility spectrometer, which includes at least three filter electrodes defining two ion flow paths where the filter electrodes generate electric fields for passing through selected portions of the sample ions based on the mobility characteristics of the sample ions. The differential mobility spectrometer also includes a voltage source that provides DC and RF voltages to at least one of the filter electrodes to generate the electric field, a first and a second ion inlet that receive sample ions, and an ion outlet that outputs the selected portion of the sample ions. A mass spectrometer receives some or all of the selected portion of the sample ions.

Abstract: An apparatus and method are provided for analyzing samples of molecules. The apparatus comprises a mass analysis system including a differential mobility spectrometer, which includes at least three filter electrodes defining two ion flow paths where the filter electrodes generate electric fields for passing through selected portions of the sample ions based on the mobility characteristics of the sample ions. The differential mobility spectrometer also includes a voltage source that provides DC and RF voltages to at least one of the filter electrodes to generate the electric field, a first and a second ion inlet that receive sample ions, and an ion outlet that outputs the selected portion of the sample ions. A mass spectrometer receives some or all of the selected portion of the sample ions.

Abstract: The present invention relates to compounds useful as inhibitors of bromodomain-containing proteins. The invention also provides pharmaceutically acceptable compositions comprising compounds of the present invention and methods of using said compositions in the treatment of various disorders.

Abstract: The present invention provides isoxazoline FAAH inhibitors of the formula (I): or pharmaceutically acceptable forms thereof, wherein each of G, Ra, Rb, Rc, and Rd are as defined herein. The present invention also provides pharmaceutical compositions comprising a compound of formula (I), or a pharmaceutically acceptable form thereof, and a pharmaceutically acceptable excipient. The present invention also provides methods for treating an FAAH-mediated condition comprising administering a therapeutically effective amount of a compound of formula (I), or pharmaceutically acceptable form thereof, to a subject in need thereof.

Abstract: A personal watercraft comprises at least one seat including a driver seating portion and at least one passenger seating portion. At least one sensor is disposed on the watercraft for detecting at least one of a presence and an absence of a passenger on the watercraft. A control unit is electrically connected to the at least one sensor. The control unit enters a first control mode in response to a signal received from the at least one sensor indicative of the presence of a passenger on the watercraft. The control unit prevents at least one performance characteristic of the watercraft from exceeding a predetermined value when in the first control mode.

Abstract: Compounds of formula I are antagonists of the PGD2 receptor, CRTH2, and as such are useful in the treatment and/or prevention of CRTH2-mediated diseases such as asthma.

Abstract: The present invention provides inhibitors of kinases, specifically I?B kinases, JAK1, JAK2, JAK3 and TYK2. The invention also provides for compositions comprising such inhibitory compounds and methods of inhibiting said kinase activity by administering the compound to a patient in need of treatment for myeloproliferative disorders, cancer or NF-?B-mediated diseases.

Abstract: A vehicle is disclosed, including a startup switch electrically connected to the ECU. Actuation of the startup switch causes a signal to be sent to the ECU indicative of a desired operation of the vehicle. A display device is disposed forwardly of the seat for displaying information to the rider. Actuation of a confirmation switch causes a confirmation signal to be sent to the ECU indicative of a display of information to a rider. Upon actuation of the startup switch, the ECU prevents the vehicle from moving until information is displayed by the display device and the confirmation signal is received by the ECU. A method of operating a vehicle is also disclosed.